3
Announcements
Trials
Browse
Landscape
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Observational
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Hepatocellular
2
Neoplasms
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Liver Neoplasms
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Anxiety Disorders
1
Interventions
Bevacizumab
47
lenvatinib
37
atezolizumab
36
durvalumab
28
tremelimumab
23
sintilimab
19
Nivolumab
18
pembrolizumab
14
Radiosurgery
13
tislelizumab
11
Specimen Handling
10
Ipilimumab
10
Immune Checkpoint Inhibitors
9
camrelizumab
8
apatinib
8
Oxaliplatin
8
Fluorouracil
8
Cyclophosphamide
8
Blood Specimen Collection
8
regorafenib
7
cabozantinib
7
fludarabine
6
Sorafenib
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Leucovorin
6
donafenib
5
Surgical Procedures, Operative
5
Injections
5
Immunoglobulin G
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Hepatocellular
×
Glutamyl Aminopeptidase
×
Clear all
NCT05713994
2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
300 enrolled
NCT05717738
2024-06-13
CCGLC-008
Tongji Hospital
Recruiting
300 enrolled